Marinus Pharmaceuticals, Inc. (MRNS) | Investment Case

1. Company Snapshot

1.a. Company Description

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders.It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.

It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome.Marinus Pharmaceuticals, Inc.has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation.

The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Show Full description

1.b. Last Insights on MRNS

Marinus Pharmaceuticals' recent performance has been driven by growing optimism about its earnings prospects, reflected in its upgrade to a "Buy" rating by a reputable firm. Additionally, the company is poised to receive $0.55 per share from its acquisition by Immedica Pharma AB, which may be viewed as a positive development for shareholders. However, the investigation into the adequacy of the sale price and process by various law firms may impact the transaction's outcome and potentially create uncertainty for shareholders.

1.c. Company Highlights

Last Price	0.55
Change Percentage	0.00%
Open	0.55
Previous Close	0.55
Market Cap ( Millions)	30
Volume	1100953
Year High	10.5
Year Low	0.22
M A 50	0.43
M A 200	1.06

FCF Yield	-169.40%
Dividend Yield	0.00%
ROE	105.28%
Debt / Equity	-83.90%
Net Debt / EBIDTA	-26.48%
Price To Book	-0.47
Price Earnings Ratio	-0.52
Price To FCF	-0.59
Price To sales	1.83
EV / EBITDA	-0.85

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Sep -27

Source: globenewswire.com

MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Jul -30

Source: globenewswire.com

Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know

Jan -10

Source: zacks.com

MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

Jan -06

Source: businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Dec -30

Source: businesswire.com

MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders

Dec -30

Source: businesswire.com

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

Dec -30

Source: businesswire.com

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates

Nov -12

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Therapeutics for Rare Seizures

Expected Growth: 10.43%

Marinus Pharmaceuticals' Therapeutics for Rare Seizures growth is driven by increasing prevalence of rare seizure disorders, high unmet medical needs, and limited treatment options. Strong clinical trial results, FDA's Orphan Drug Designation, and potential for expedited regulatory approval also contribute to the growth. Additionally, partnerships and collaborations with key opinion leaders and patient advocacy groups support the therapy's adoption.

7. Detailed Products

Ganaxolone

Ganaxolone is a neuroactive steroid that is being developed as a potential treatment for epilepsy, postpartum depression, and other neurological disorders.

IV Ganaxolone

IV Ganaxolone is a proprietary, water-soluble formulation of ganaxolone that is being developed as a potential treatment for status epilepticus.

8. Marinus Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Marinus Pharmaceuticals, Inc. faces moderate threat from substitutes, as there are limited alternative treatments available for epilepsy and other central nervous system disorders.

Bargaining Power Of Customers

Marinus Pharmaceuticals, Inc. has a diverse customer base, which reduces the bargaining power of individual customers, and the company's products are not easily substitutable.

Bargaining Power Of Suppliers

Marinus Pharmaceuticals, Inc. relies on a few key suppliers for raw materials and manufacturing services, which gives them some bargaining power, but the company's strong relationships and contracts mitigate this risk.

Threat Of New Entrants

The pharmaceutical industry is highly competitive, and new entrants can easily disrupt the market with innovative products and technologies, posing a significant threat to Marinus Pharmaceuticals, Inc.'s market share.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players and new entrants vying for market share, leading to intense rivalry and pricing pressure for Marinus Pharmaceuticals, Inc.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	86.75%
Debt Cost	9.64%
Equity Weight	13.25%
Equity Cost	9.64%
WACC	9.64%
Leverage	654.49%

11. Quality Control: Marinus Pharmaceuticals, Inc. passed 4 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Adaptive Biotechnologies

A-Score: 4.4/10

Value: 6.0

Growth: 3.8

Quality: 4.7

Yield: 0.0

Momentum: 10.0

Volatility: 1.7

1-Year Total Return ->

Tonix Pharmaceuticals

A-Score: 4.2/10

Value: 7.6

Growth: 5.2

Quality: 3.8

Yield: 0.0

Momentum: 8.5

Volatility: 0.3

1-Year Total Return ->

AnaptysBio

A-Score: 4.1/10

Value: 8.2

Growth: 3.2

Quality: 5.0

Yield: 0.0

Momentum: 6.5

Volatility: 1.7

1-Year Total Return ->

Marinus Pharmaceuticals

A-Score: 3.7/10

Value: 9.0

Growth: 6.2

Quality: 6.1

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

Biora Therapeutics

A-Score: 3.0/10

Value: 8.8

Growth: 3.4

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

Senti Biosciences

A-Score: 2.5/10

Value: 7.0

Growth: 2.9

Quality: 2.9

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

14.32%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

9.64%

Marinus Pharmaceuticals, Inc. - US56854Q2003

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on MRNS

1.c. Company Highlights

Weak Momentum

Cheaper

Medium Volatility

Revenues Miss

Earnings Miss

Fairly Valued

Earnings Beats

More Volatile

Stable Momentum

Average Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Therapeutics for Rare Seizures

Expected Growth: 10.43%

7. Detailed Products

Ganaxolone

IV Ganaxolone

8. Marinus Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Marinus Pharmaceuticals, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.55$

Current Price

0.55$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA